VIDEO: T-DXd shows promise for patients with HER2-positive breast cancer with brain metastases
Click Here to Manage Email Alerts
Trastuzumab deruxtecan, or T-DXd, showed clinical activity in a large population of metastatic HER2-positive breast cancer patients with brain metastases, according to “really impressive” data from DESTINYBreast-12 presented at ESMO Congress.
“In my mind, these data really establish T-DXd [Enhertu; AstraZeneca, Daichii Sankyo] as standard of care, not just for systemic disease in the second-line setting, but also for those patients who may have brain metastases,” Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, told Healio in a video interview.
“I think this was really critical data for us to have because about 50% of our patients with metastatic HER2-positive breast cancer will develop brain metastases in their lifetime — so really important for us to not just understand how these drugs work in the rest of the body, but also in the brain,” she added.
Reference:
Collapse
Read more about
Click Here to Manage Email Alerts